Arcutis director trades 4,730 shares at $24.18

A director of Arcutis Biotherapeutics exercised options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. director Howard G. Welgus reported multiple option exercises and a share sale in Arcutis (ARQT) on September 15, 2026. He exercised stock options to acquire an aggregate 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, all from fully vested options. On the same date, he sold 4,730 shares of common stock at $24.18 per share in an open-market or private transaction. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Welgus Howard G.

Role Director

Sold 4,730 shs ($114K)

Approx. gross sale proceeds $114K

Approx. exercise cost $32K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F2	822	$0.00	$0.00
Exercise	Stock Option (right to buy) F1, F2	1,019	$0.00	$0.00
Exercise	Stock Option (right to buy) F1, F2	2,255	$0.00	$0.00
Exercise	Common Stock F1	822	$6.5223	$5K
Exercise	Common Stock F1	1,019	$7.51	$8K
Exercise	Common Stock F1	2,255	$8.63	$19K
Sale	Common Stock F1	4,730	$24.18	$114K

Holdings After Transaction: Stock Option (right to buy) — 32,750 contracts (Direct); Common Stock — 35,841 shares (Direct)

Footnotes (2)

1. F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
2. F2. The option is fully vested.

Key Figures

Options exercised at $6.5223: 822 shares Options exercised at $7.51: 1,019 shares Options exercised at $8.63: 2,255 shares +5 more

8 metrics

Options exercised at $6.5223 822 shares Stock options exercised into common stock on September 15, 2026

Options exercised at $7.51 1,019 shares Stock options exercised into common stock on September 15, 2026

Options exercised at $8.63 2,255 shares Stock options exercised into common stock on September 15, 2026

Total shares acquired via option exercise 4,096 shares Aggregate underlying common stock from three option exercises

Shares sold 4,730 shares Common stock sold on September 15, 2026

Sale price per share $24.18 per share Price for the 4,730 common shares sold

10b5-1 plan adoption date March 13, 2026 Adoption date of trading plan governing the reported transactions

10b5-1 plan end date June 15, 2027 Plan end date for the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), Common Stock, open market or private transaction

4 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"security title is listed as Stock Option (right to buy)"

Common Stock financial

"underlying security title and transaction security title as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ARQT director Howard G. Welgus report on this Form 4?

He reported exercising stock options for a total of 4,096 ARQT shares and selling 4,730 ARQT common shares on September 15, 2026, in an open-market or private transaction.

How many Arcutis Biotherapeutics (ARQT) options did the director exercise and at what prices?

He exercised options covering 822 shares at $6.5223, 1,019 shares at $7.51, and 2,255 shares at $8.63 per share, for a total of 4,096 ARQT shares of common stock acquired through option exercises.

How many ARQT shares did the director sell and at what price?

He sold 4,730 shares of Arcutis Biotherapeutics common stock at a price of $24.18 per share on September 15, 2026, in a transaction reported as a sale in the open market or a private transaction.

Were the ARQT insider transactions made under a Rule 10b5-1 trading plan?

Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027, as disclosed in the footnotes.

What role does Howard G. Welgus have at Arcutis Biotherapeutics (ARQT)?

Howard G. Welgus is reported as a director of Arcutis Biotherapeutics, Inc. on this Form 4. The filing does not identify him as an officer or ten percent owner.

Are the options exercised by the ARQT director fully vested?

Yes. A footnote states that “The option is fully vested”, indicating that the stock options exercised for the reported transactions were fully vested at the time of exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:07 PM Accepted by SEC EDGAR 09/17/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M(1)		822	A	$6.5223	37,297	D
Common Stock	09/15/2026		M(1)		1,019	A	$7.51	38,316	D
Common Stock	09/15/2026		M(1)		2,255	A	$8.63	40,571	D
Common Stock	09/15/2026		S(1)		4,730	D	$24.18	35,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.5223	09/15/2026		M(1)			822	(2)	11/20/2029	Common Stock	822	$0	6,574	D
Stock Option (right to buy)	$7.51	09/15/2026		M(1)			1,019	(2)	05/31/2033	Common Stock	1,019	$0	8,144	D
Stock Option (right to buy)	$8.63	09/15/2026		M(1)			2,255	(2)	06/14/2034	Common Stock	2,255	$0	18,032	D

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

2. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)